Global /China /Healthcare /Biotechnology /300482
chevron_leftBack
Guangzhou Wondfo Biotech Co.,Ltd logo

Guangzhou Wondfo Biotech Co.,Ltd

300482
SHE: 300482 Delayed
18.29CNY -1.9%
2.70 USD
As of 16 June 2026, Guangzhou Wondfo Biotech Co.,Ltd has a market cap of $1.28B USD, ranking #9325 globally and #2500 in China. It ranks #792 in the Healthcare sector, and #154 in the Biotechnology industry.
Global Rank
9325
Country Rank
2500
Sector Rank
792
Industry Rank
154
Key Stats
Market Cap
$1.28BUSD
8.66B CNY
Enterprise Value
$1.07BUSD
7.22B CNY
Revenue (TTM)
$275.91MUSD
1.87B CNY
EBITDA (TTM)
-$2.15MUSD
-14.57M CNY
Net Income (TTM)
-$24.77MUSD
-167.76M CNY
EBITDA Margin
-0.8%
Profit Margin
-9%
Forward PE
20.7
PS Ratio
4.6
PB Ratio
1.6
EV/EBITDA
70.1
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Biotechnology
CEO
Zhongxiong Peng open_in_new
Employees
3,197
Founded
1992
Website
wondfo.com.cn open_in_new
warningChart data may be delayed
1d 1w 1m 3m 6m 1y
-1.9% 16% -0.7% -15% -13% -10%

News

Loading...

Markets

Exchange Ticker Price
Shenzhen Stock Exchange
MIC: XSHE
PRIMARY
300482
广州万孚生物技术股份有限公司 Class A
ISIN: CNE100002102
Shares Out.:
466.657M1 Shares Float: 266.734M2
TV:
SA:
YF:
GF:
BA:
MS:
18.29 CNY
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.

About Guangzhou Wondfo Biotech Co.,Ltd

Guangzhou Wondfo Biotech Co.,Ltd, an in vitro diagnostics company, engages in the research and development, production, market, sale, and service of vitro diagnostic products in China. The company offers rapid test kits for COVID-19, drug of abuse, tumor, infectious disease, fertility, tumor marker, and sexually transmitted diseases; immunofluorescence platform for detecting cardiac, thyroid, rheumatoid arthritis, sex hormone, anemia, gastroenterology, hypertension, thrombus, tumor, inflammation, diabetes, allergy, respiratory infection, kidney, brain injury, bone metabolism, and infectious disease; and chemiluminescence platform. It also provides semi-automatic blood coagulation analyzer and optical blood coagulation; automatic blood gas biochemical analyzer and blood gas analyzer; molecular diagnostics platform; fully automated pathology straining system; and fully automatic HbAlc analyzer. In addition, the company offers solutions, such as new-generation vitamin D, wondfo CRP campaign, international public health solutions, POCT lab, and COVID-19 total solution. Its products are used in clinical testing, critical illness, chronic disease management, primary care, epidemic monitoring, disaster relief, on-site law enforcement, and family personal health management. The company was founded in 1992 and is based in Guangzhou, China.

Similar Companies

Industry: Biotechnology (China)
Name
Market Cap diff.
PE
$17.45B
136.71B HKD
1K%
25.3
$12.2B
95.58B HKD
853%
22.1
$8.01B
54.23B CNY
526%
34.4
$7.34B
49.69B CNY
474%
-
1530
$7.08B
55.5B HKD
454%
5.8
$6.72B
45.52B CNY
425%
61.6
Industry: Biotechnology (Global)
Name
Market Cap diff.
PE
AMGN
$182.42B
14K%
23.9
GILD
$159.92B
12K%
19.0
ARGX
$47.89B
41.39B EUR
4K%
39.9
$45.02B
68.19T KRW
3K%
35.5
CSL
$42.64B
60.27B AUD
3K%
29.3
LONN
$42.17B
33.71B CHF
3K%
37.2
chevron_leftBack